Cellectis could cut 70% of workforce in shift to in vivo therapies
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- CLLS Cellectis S.A
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Cellectis S.A belongs to, so it often moves with news about it.
- BNTX BioNTech SE-9.2% 9d
BioNTech SE is a peer of Cellectis S.A in biological products, (no diagnostic substances); rivals often move on the same news.
- NBIX Neurocrine Biosciences+16.5% 9d
Neurocrine Biosciences is a peer of Cellectis S.A in biological products, (no diagnostic substances); rivals often move on the same news.
- QGEN Qiagen N.V
Qiagen N.V is a peer of Cellectis S.A in biological products, (no diagnostic substances); rivals often move on the same news.
- CRSP CRISPR Therapeutics AG-23.0% 30d
CRISPR Therapeutics AG is a peer of Cellectis S.A in biological products, (no diagnostic substances); rivals often move on the same news.
- AMGN Amgen+15.9% 30d
Amgen is a peer of Cellectis S.A in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CLLS | -18.32% | -12.98% | base | -12.21% | after close | after close | after close |
| XLV | -1.60% | +0.57% | base | +0.61% | after close | after close | after close |
| BNTX | +2.97% | +2.56% | base | +0.76% | after close | after close | after close |
| NBIX | -2.76% | -0.17% | base | -0.55% | after close | after close | after close |
| QGEN | +0.42% | +0.82% | base | -0.39% | after close | after close | after close |
| CRSP | +17.59% | +6.15% | base | +0.16% | after close | after close | after close |
| AMGN | -1.47% | -0.45% | base | -0.15% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Cellectis could cut 70% of workforce in shift to in vivo therapies BioSpace
Source: BioSpace
This story
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | -0.15% | still updating |
| AMGN | three days earlier | -0.45% | final price |
| AMGN | five days earlier | -1.47% | final price |
| BNTX | that day | +0.76% | still updating |
| BNTX | three days earlier | +2.56% | final price |
| BNTX | five days earlier | +2.97% | final price |
| CLLS | that day | -12.21% | still updating |
| CLLS | three days earlier | -12.98% | final price |
| CLLS | five days earlier | -18.32% | final price |
| CRSP | that day | +0.16% | still updating |
| CRSP | three days earlier | +6.15% | final price |
| CRSP | five days earlier | +17.59% | final price |
| NBIX | that day | -0.55% | still updating |
| NBIX | three days earlier | -0.17% | final price |
| NBIX | five days earlier | -2.76% | final price |
| QGEN | that day | -0.39% | still updating |
| QGEN | three days earlier | +0.82% | final price |
| QGEN | five days earlier | +0.42% | final price |
| XLV | that day | +0.61% | still updating |
| XLV | three days earlier | +0.57% | final price |
| XLV | five days earlier | -1.60% | final price |
This story
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $15,001 - $50,000 on 15 Oct 2026. That is 29 days before publication. Filed 2 Nov 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 52 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 79 days before publication. Filed 5 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100Price not final
“Cellectis could cut 70% of workforce in shift to in vivo therapies” scores 12 out of 100. The score uses 1 sources. The price is not final yet.